Endometrial cancer: news from ASCO

In conclusion, checkpoint inhibitors ± lenvatinib are now established in the second-line treatment of advanced endometrial cancer. Overall, the inclusion of PD1 or PDL1 inhibitors in systemic treatment regimens offers a significant opportunity for patients whose treatment options i n the past only included conventional chemotherapy, radiotherapy or hormonal therapy.
Source: Memo - Magazine of European Medical Oncology - Category: Cancer & Oncology Source Type: research